Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment.
about
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsCurrent and future therapies for gout.Management of Gout and Hyperuricemia in CKD.The safety of treatment options available for gout.Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure.Risk of Febuxostat-Associated Myopathy in Patients with CKD.The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.Cardiac and renal protective effects of urate-lowering therapy.Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article.Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi et al.Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
P2860
Q33864537-A3085080-352A-4A19-A0CB-D5073630ECF8Q38660829-24BA565D-5FF8-4C97-805D-1D314061B0EAQ38812962-73606257-BEE3-4D18-A103-B731D5F0D827Q39092018-255EDC47-384E-4BA3-8D12-332D214ACC2BQ39687173-24917DF2-9FE2-465C-85B5-6762C3713BFEQ40288477-F73D92CC-B3F5-42FB-AF14-D9FF72345A75Q47099047-3EC6B2B4-02F2-4F9B-B7C5-C406744011AAQ47169238-2C97F04B-D55A-42A4-96A1-820F26536A9AQ47658083-34C9362D-B29D-4BE6-9005-8701CD1E457BQ48209584-69F9D1E8-00F7-47A9-898D-F0CA569F958EQ49616077-9A26D864-D571-4F32-B13B-888FC803859AQ52622926-3EAACDFA-B8CE-4AF0-B233-7A399E944DBFQ54298991-EC71E7BA-69AE-4AE7-8328-6A86E932CB59Q55284599-EB51B301-0A00-4271-B4E9-5EC861E00CA9
P2860
Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Impact of Febuxostat on Renal ...... te-to-Severe Renal Impairment.
@en
Impact of Febuxostat on Renal ...... te-to-Severe Renal Impairment.
@nl
type
label
Impact of Febuxostat on Renal ...... te-to-Severe Renal Impairment.
@en
Impact of Febuxostat on Renal ...... te-to-Severe Renal Impairment.
@nl
prefLabel
Impact of Febuxostat on Renal ...... te-to-Severe Renal Impairment.
@en
Impact of Febuxostat on Renal ...... te-to-Severe Renal Impairment.
@nl
P2093
P2860
P356
P1476
Impact of Febuxostat on Renal ...... te-to-Severe Renal Impairment.
@en
P2093
Andrew Whelton
Barbara Hunt
Kenneth G Saag
Lhanoo Gunawardhana
Michael A Becker
Patricia MacDonald
P2860
P304
P356
10.1002/ART.39654
P577
2016-02-19T00:00:00Z